TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Apple Turns 50: From Garage Startup to AI Crossroads 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
SAN DIEGO, Oct. 06, 2016 -- Retrophin, Inc. (Nasdaq:RTRX) today announced Alvin Shih, M.D., will be stepping down from his position as executive vice president and head of research and development to become chief executive officer of a start-up biotechnology company. Dr. Shih will remain in his current role until October 31, 2016 and has agreed to serve as a consultant to Retrophin thereafter. The Company has initiated a search for a permanent successor. In the interim, chief executive officer Stephen Aselage will assume responsibility of the research and development organization.
“On behalf of the board and all our employees, I want to thank Alvin for his tremendous contributions to the rapid progression of our pipeline,” said Mr. Aselage. “Alvin is leaving us in a strong position to continue the advancement of sparsentan and RE-024; we wish him success in his new role.”
“While I am sad to leave Retrophin, I’m incredibly proud of the progress we have made towards delivering new therapies for rare disease patients,” said Dr. Shih. “I look forward to contributing to Retrophin’s future success as an external advisor.”
About Retrophin
Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company’s approach centers on its pipeline featuring clinical-stage assets targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets in several rare diseases is also underway. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Thiola®, Cholbam® and Chenodal®.
Contact: (Investors) Chris Cline, CFA Senior Director, Investor Relations 646-564-3680 [email protected]
